Edwards Lifesciences Raises 2026 Outlook

Edwards Lifesciences Raises 2026 Outlook
Edwards Lifesciences has significantly raised its financial guidance for 2026, projecting sales growth between 9% and 11%, with adjusted earnings per share expected to reach $2.95 to $3.05. This optimistic forecast reflects strong operational momentum and confidence in the company's core business segments. The company's transcatheter aortic valve replacement (TAVR) division is driving much of this growth, with Edwards now guiding TAVR sales to expand 7% to 9% during 2026. This acceleration demonstrates robust market demand for minimally invasive cardiac procedures and Edwards' dominant market position in this critical therapeutic area. The TAVR segment continues to benefit from expanding patient populations, aging demographics, and increasing adoption rates across global markets.